Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2016

View Archived Issues

Ember Therapeutics acquires ICX-RHY from Intercytex

68Ga-DOTA-E[c(RGDfK)]2 as potential tracer for tumor angiogenesis imaging

Fujifilm demonstrates potential of Cellnest in bone regeneration

Lilly reports FFA1 receptor agonists for type 2 diabetes

FDA grants orphan drug designation to SPK-TPP1 for the treatment of CLN2 disease

Merck & Co. patents DGAT-2 inhibitors

CTxT Pty discloses PRMT5 inhibitors

FLT3 and JAK inhibitors described in Pierre Fabre patent

Toray Industries introduces IL-23 receptor ligands

CHDI Foundation reports PET probes

Pfizer divulges JAK inhibitors

Anti-Notch 3 ADC from Pfizer shows signs of efficacy in phase I study

Ajinomoto and Mochida to jointly develop AJG-533 in Japan

New role of RUNX3 as a prognostic biomarker for diffuse large B-cell lymphoma

Ono seeks Japanese approval of Opdivo for relapsed or refractory Hodgkin's lymphoma

Cymbalta approved in Japan for chronic lower back pain

New animal model to study the role of Maspin in prostatic intraepithelial hyperplasia

The Garvan Institute of Medical Research receives funding from NHMRC

Sumitomo Dainippon discovers novel orally available human neutrophil elastase inhibitors

Eisai announces discontinuation of sales and voluntary recall of egg white lysozyme preparation

Promising topline data from phase III study of romosozumab in men with osteoporosis

Omnis Pharma and Magnis Therapeutics merge to form Vyriad

Symphogen initiates phase I/II trial of Sym-015 in advanced solid tumor malignancies

miR-122-5p shows promise as a biomarker for liver injury

Affymetrix continues to recommend Thermo Fisher merger following Origin proposal

Proemend approved in Japan for CINV in pediatic patients

ProMIS Neurosciences identifies third therapeutic target for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...